Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal
Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up…
Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up…
Despite widespread clinical trial delays caused by the coronavirus pandemic, many oncology biotechs have been…
Lyon-based biopharmaceutical company Tollys has closed a Series A funding round of €2.3M to bring…
An oversubscribed Series B2 round has seen the biopharmaceutical company iTeos Therapeutics raise €114M, which…
With one foot in Belgium and another in the US, Orionis Biosciences combines US and…
UK biotech Bicycle Therapeutics will collaborate with Genentech, now part of the Roche Group, to…
With the success of CAR T-cell therapies and other innovative medicines in this area, immuno-oncology…
Through quirks of genetics, some people are naturally resilient to heritable diseases. Thijn Brummelkamp, Managing…
The Portuguese company CellmAbs is developing cancer immunotherapies that prevent tumor cells from evading the…
The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the…
The French-Belgian company PDC*Line Pharma has raised a €20M Series B round to fund an…
Alderaan Biotechnology has raised an €18.5M Series A round to push its lead cancer immunotherapy…